TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Indivior ( (INDV) ) has shared an announcement.
On November 20, 2025, Indivior PLC announced the conclusion of its legacy matter with the U.S. Department of Justice by paying the remaining $295 million obligation. This payment, funded from the company’s cash reserves, terminates the resolution agreement with the DOJ, removing a significant liability and simplifying Indivior’s capital structure.
The most recent analyst rating on (INDV) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Indivior stock, see the INDV Stock Forecast page.
Spark’s Take on INDV Stock
According to Spark, TipRanks’ AI Analyst, INDV is a Neutral.
Indivior’s overall stock score is driven by strong earnings call results and positive technical indicators, despite valuation concerns and financial stability issues. The company’s growth prospects and strategic initiatives are promising, but high leverage and overvaluation pose risks.
To see Spark’s full report on INDV stock, click here.
More about Indivior
Indivior is a pharmaceutical company focused on developing medicines to treat opioid use disorder (OUD). The company aims to transform OUD from a human crisis to a recognized and treated chronic disease, offering a range of treatments and a pipeline of product candidates in this category.
Average Trading Volume: 2,163,038
Technical Sentiment Signal: Buy
Current Market Cap: $4.07B
Find detailed analytics on INDV stock on TipRanks’ Stock Analysis page.